BACKGROUND: The importance of chronic inflammation as a determinant of aging phenotypes may have been underestimated in previous studies that used a single measurement of inflammatory markers. We assessed inflammatory markers twice over a 5-year exposure period to examine the association between chronic inflammation and future aging phenotypes in a large population of men and women. METHODS: We obtained data for 3044 middle-aged adults (28.2% women) who were participating in the Whitehall II study and had no history of stroke, myocardial infarction or cancer at our study's baseline (1997-1999). Interleukin-6 was measured at baseline and 5 years earlier. Cause-specific mortality, chronic disease and functioning were ascertained from hospital data, register linkage and clinical examinations. We used these data to create 4 aging phenotypes at the 10-year follow-up (2007-2009): successful aging (free of major chronic disease and with optimal physical, mental and cognitive functioning), incident fatal or nonfatal cardiovascular disease, death from noncardiovascular causes and normal aging (all other participants). RESULTS: Of the 3044 participants, 721 (23.7%) met the criteria for successful aging at the 10-year follow-up, 321 (10.6%) had cardiovascular disease events, 147 (4.8%) died from noncardiovascular causes, and the remaining 1855 (60.9%) were included in the normal aging phenotype. After adjustment for potential confounders, having a high interleukin-6 level (> 2.0 ng/L) twice over the 5-year exposure period nearly halved the odds of successful aging at the 10-year follow-up (odds ratio [OR] 0.53, 95% confidence interval [CI] 0.38-0.74) and increased the risk of future cardiovascular events (OR 1.64, 95% CI 1.15-2.33) and noncardiovascular death (OR 2.43, 95% CI 1.58-3.80). INTERPRETATION: Chronic inflammation, as ascertained by repeat measurements, was associated with a range of unhealthy aging phenotypes and a decreased likelihood of successful aging. Our results suggest that assessing long-term chronic inflammation by repeat measurement of interleukin-6 has the potential to guide clinical practice.
BACKGROUND: The importance of chronic inflammation as a determinant of aging phenotypes may have been underestimated in previous studies that used a single measurement of inflammatory markers. We assessed inflammatory markers twice over a 5-year exposure period to examine the association between chronic inflammation and future aging phenotypes in a large population of men and women. METHODS: We obtained data for 3044 middle-aged adults (28.2% women) who were participating in the Whitehall II study and had no history of stroke, myocardial infarction or cancer at our study's baseline (1997-1999). Interleukin-6 was measured at baseline and 5 years earlier. Cause-specific mortality, chronic disease and functioning were ascertained from hospital data, register linkage and clinical examinations. We used these data to create 4 aging phenotypes at the 10-year follow-up (2007-2009): successful aging (free of major chronic disease and with optimal physical, mental and cognitive functioning), incident fatal or nonfatal cardiovascular disease, death from noncardiovascular causes and normal aging (all other participants). RESULTS: Of the 3044 participants, 721 (23.7%) met the criteria for successful aging at the 10-year follow-up, 321 (10.6%) had cardiovascular disease events, 147 (4.8%) died from noncardiovascular causes, and the remaining 1855 (60.9%) were included in the normal aging phenotype. After adjustment for potential confounders, having a high interleukin-6 level (> 2.0 ng/L) twice over the 5-year exposure period nearly halved the odds of successful aging at the 10-year follow-up (odds ratio [OR] 0.53, 95% confidence interval [CI] 0.38-0.74) and increased the risk of future cardiovascular events (OR 1.64, 95% CI 1.15-2.33) and noncardiovascular death (OR 2.43, 95% CI 1.58-3.80). INTERPRETATION: Chronic inflammation, as ascertained by repeat measurements, was associated with a range of unhealthy aging phenotypes and a decreased likelihood of successful aging. Our results suggest that assessing long-term chronic inflammation by repeat measurement of interleukin-6 has the potential to guide clinical practice.
Authors: Nancy S Jenny; Benjamin French; Alice M Arnold; Elsa S Strotmeyer; Mary Cushman; Paulo H M Chaves; Jingzhong Ding; Linda P Fried; Stephen B Kritchevsky; Dena E Rifkin; Mark J Sarnak; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2012-02-24 Impact factor: 6.053
Authors: Katriina Heikkilä; Shah Ebrahim; Ann Rumley; Gordon Lowe; Debbie A Lawlor Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06 Impact factor: 4.254
Authors: John Danesh; Stephen Kaptoge; Andrea G Mann; Nadeem Sarwar; Angela Wood; Sara B Angleman; Frances Wensley; Julian P T Higgins; Lucy Lennon; Gudny Eiriksdottir; Ann Rumley; Peter H Whincup; Gordon D O Lowe; Vilmundur Gudnason Journal: PLoS Med Date: 2008-04-08 Impact factor: 11.069
Authors: Stephen Kaptoge; Emanuele Di Angelantonio; Gordon Lowe; Mark B Pepys; Simon G Thompson; Rory Collins; John Danesh Journal: Lancet Date: 2009-12-22 Impact factor: 79.321
Authors: Tasnime Akbaraly; Séverine Sabia; Gareth Hagger-Johnson; Adam G Tabak; Martin J Shipley; Markus Jokela; Eric J Brunner; Mark Hamer; G David Batty; Archana Singh-Manoux; Mika Kivimaki Journal: Am J Med Date: 2013-05 Impact factor: 4.965
Authors: Ruozhen Hu; Dominique A Kagele; Thomas B Huffaker; Marah C Runtsch; Margaret Alexander; Jin Liu; Erin Bake; Wei Su; Matthew A Williams; Dinesh S Rao; Thomas Möller; Gwenn A Garden; June L Round; Ryan M O'Connell Journal: Immunity Date: 2014-10-16 Impact factor: 31.745
Authors: Jennifer St Sauver; Walter Rocca; Nathan LeBrasseur; Alanna Chamberlain; Janet Olson; Debra Jacobson; Michaela McGree; Michelle Mielke Journal: J Int Med Res Date: 2022-07 Impact factor: 1.573
Authors: Elisa Fabbri; Yang An; Marco Zoli; Eleanor M Simonsick; Jack M Guralnik; Stefania Bandinelli; Cynthia M Boyd; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2014-08-07 Impact factor: 6.053